This Article  • Excerpt  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Dermatol. 1994;130(2):153-154.

References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

* Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services. ** CDC's 1993 Sexually Transmitted Diseases Treatment Guidelines state that the safety of systemic acyclovir therapy among pregnant women has not been established. In the presence of life-threatening maternal herpes simplex virus infections (e.g. disseminated infection that includes encephalitis, pneumonitis, and/or hepatitis), acyclovir administered intravenously is indicated. Among pregnant women without life-threatening disease, systemic acyclovir treatment should not be used for recurrences nor should it be used as suppressive therapy near term (or other times during pregnancy) to prevent reactivation.2 *** Australia, Bermuda, Canada, Czech Republic, Finland, France, Germany, Greece, Ireland, Malaysia, New Zealand, Oman, South Africa, Spain, Sweden, the Netherlands, the United Kingdom, and the United States. **** Pregnancy category C indicates that the risk associated with drug exposure to the fetus is unclear because human studies are lacking, and animal studies are either positive for fetal risk or lacking. However, potential benefits may justify the potential risk. FDA's pregnancy categories are based on the degree to which available information has ruled out risk to the fetus. Ratings range from "A," for drugs that have been tested for teratogenicity under controlled conditions without showing evidence of damage to the fetus, to "D" for drugs that are teratogenic but have no safer alternatives. An "X" rating is reserved for drugs that should never be used during pregnancy. 1. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989;321:7-12. ABSTRACT 2. CDC. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993;42(no. RR-14)(in press). 3. CDC. Congenital malformations surveillance report, January 1982-December 1985. Atlanta: US Department of Health and Human Services, Public Health Service, 1988.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?